A Phase I, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of XG2002 Oral Administration in Healthy Adult Volunteers
Xgene Pharmaceutical Pty Ltd
32 participants
Apr 15, 2024
Interventional
Conditions
Summary
This is a randomised, double-blind, placebo-controlled, First-in-Human Study to assess the safety ofXG2002 and how this drug acts in the body in healthy volunteers. XG2002 may be indicated for use in patients with acute and chronic pain, but a trial of the drug in healthy volunteers is needed before trials in patients suffering from acute and chronic pain can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 65 years and are in good general health without a clinically significant medical history. Study details All healthy volunteer participants who choose to enrol in this study will be assigned by chance to receive either a single dose of XG2002 or placebo. All participants will have their vital signs checked (heart rate, blood pressure with Core Body Temperature (CBT) being measured by an ingested real-time monitoring device), and will provide blood and urine samples for testing. If the drug appears safe, additional participants will be assigned by chance to receive a larger single dose of XG2002 or placebo, followed by blood and urine testing. This will continue until a maximum safe dose is determined. It is hoped this research will determine the maximum dose of XG2002 that can be administered safely without causing severe reactions. Once the dose of XG2002 has been determined in healthy volunteers, a trial investigating the efficacy of XG2002 as a treatment for patients with acute and chronic pain may proceed.
Eligibility
Inclusion Criteria14
- Healthy male or female volunteers between 18 and 65 years of age, inclusive (at the
- time of ICF).
- Weight greater than or equal to 60 kg and a Body Mass Index (BMI) 18.0 to 35.0 kg/m2, inclusive.
- Medically healthy, with no clinically significant medical conditions in the opinion of the Investigator.
- Able to comprehend and provide voluntarily signed informed consent form, and to abide by the study restrictions and requirements.
- Non-pregnant, non-breastfeeding female subjects may be enrolled if they are:
- a. Surgically sterilized (verbal confirmation acceptable) or postmenopausal
- (amenorrhea greater than or equal to 1 year and follicle-stimulating hormone greater than or equal to 30 mU/mL); or
- b. Practicing true abstinence or an effective method of contraception from Screening visit until 3 months following the last dose of study drug, and must have a negative serum pregnancy test (women of childbearing potential [WOCBP] only) at screening and a negative urine pregnancy test (WOCBP only) on Day -1.
- Male subjects may be enrolled if they are:
- a. Surgically sterilized (vasectomy – verbal confirmation acceptable); or
- b. Practicing true abstinence from Screening visit until 90 days following the last dose of study drug; or
- c. Willing to use a condom during sexual activity, plus appropriate contraceptive measures for his female partner from Screening visit until 90 days after the last dose of study drug. This requirement does not apply to subjects in a same sex relationship and female partners of non-childbearing potential; and
- d. Do not donate sperm for 90 days after last dose of study drug (non- vasectomized subjects).
Exclusion Criteria19
- Subjects with unstable or severe illness, including clinically significant malignancy, of hepatic, pulmonary, metabolic, neurologic, cardiovascular, gastrointestinal (e.g., inflammatory bowel disease), haematological, or psychiatric as indicated on medical history, physical examination, or clinical laboratory, vital signs, and ECGs evaluations, or in the opinion of the Investigator.
- Subjects with clinically significant history of medical condition (in the opinion of the Investigator).
- Subjects with any report of acute illness or febrile event that has not been resolved within 72 hours prior to dosing.
- Subjects with any of the following laboratory test results at Screening:
- a. creatinine clearance < 90 mL/min (estimated using the Cockcroft and Gault equation)
- b. elevation of liver function tests: ALT, AST, GGT, bilirubin, or alkaline phosphatase > 1.5 times of the upper limit of normal range
- c. leucocytes or lymphocytes < 1.5 times of the lower limit of normal
- d. hemoglobin < the normal range of corresponding gender
- Subjects with positive results for hepatitis B surface antigen (HbsAg) and/or hepatitis B anticore antibody (anti-HBc) but negative results for anti-surface antibody (antiHBs) at Screening visit
- Positive results for hepatitis C antibody unless patient received curative therapy and a negative viral load is documented.
- Human immunodeficiency virus (HIV) infection or positive HIV serology at the Screening Visit.
- Subjects who have smoked more than 5 tobacco or nicotine-containing product (including nicotine patches) per week for 90 days prior to screening through to the end of the study.
- Positive urine drug screen at Screening and Day -1, or positive alcohol breath test on Day -1.
- Subjects who have not abstained from alcoholic beverages/alcohol-containing products at least 72 hours prior to drug administration, or plan to consume them through the completion of the follow-up visit.
- Sleep pills 3 days prior to randomization and for the duration of the study
- Unless a specific dietary need can be catered for at the study site, subjects with an abnormal diet including lactose/gluten intolerance, food rich with capsaicin or causing dysgeusia or other dietary restrictions (except vegetarian/vegan or religious dietary requirements), as determined by the Investigator 30 days prior to the study dosing.
- Subjects with a history of donation of blood or blood products, or significant blood loss (>480ml) within 30 days prior to the study dosing.
- Participation in another clinical trial with medicinal intervention within 30 days or 5 half-lived, whichever is longer, prior to the study dose.
- Known or suspected hypersensitivity or idiosyncratic reaction to the study drug or its excipient.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is a double-blind, placebo-controlled, randomised, single dose escalation study. Approximately 48 participants will be enrolled sequentially into six ascending dose cohorts and will be randomised to receive either XG2002 or placebo as an oral capsule on Day 1. Participants in each cohort will be required to fast for approximately 10 hours overnight prior to dosing on Day 1 with the dose ranging from 10 mg - 800mg of either XG2002 or matching placebo. Core Body Temperature (CBT) will be measured by an ingested real-time monitoring device. Dose escalation in each successive dose cohort will proceed in a sequential fashion after all relevant safety and tolerability data from all completed cohorts including the preceding dose cohort(s) have been reviewed by the Safety Review Committee (SRC). If it is not appropriate to escalate the dose level according to the proposed dose escalation schedule or intolerable dose level encountered (i.e., Stopping Criteria met), then an alternative sub-level dose may be given following discussion between the Sponsor and SRC (for example, if 800 mg dose is the intolerable dose, a cohort for 600 mg may be tested). Adherence to study intervention will be conducted by study staff and recorded in the source document.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12624000245594